| Company Name: | Tiens Biotech Group USA | | Ticker Symbol: | TBV | | | WWW Address: | www.tiens-bio.com | | CEO: | Jinyuan Li | | No. of Employees: | 1,549 | | Common Issue Type: | CS | | Business Description: | The Company researches, develops, manufactures, and markets nutrition supplement products, including wellness products and dietary supplement products.
|
| | | Industry Information: | DRUGS - Drug Related Products & Accessories [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 4.68 |  -0.14 | 4.08 | 5.93 | 4.8501 | 4.85 | 4.60 | 29622 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 333.8 | 71.3 | 2.03 | 0.39 | 0.00 | 13.0 | 0.0 | 5.64 - 0.91 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 4.68 | $ | | PE Ratio - LTM | 13.0 | |
| Market Capitalisation | 333.8 | mil |
| Latest Shares Outstanding | 71.3 | mil |
| Earnings pS (EPS) | 0.39 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 49,870 | $ |
| Effective Tax Rate | 7.3 | % |
| Float | 3.5 | mil |
| Float as % of Shares Outstanding | 4.9 | % |
| Foreign Sales | 44 | mil |
| Domestic Sales | 34 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 23.60 | % |
| Research & Devlopment (R&D) as % of Revenue | 0.00 | % |
| Gross Profit Margin | 69.5 | % |
| EBITDA Margin | 46.0 | % |
| Pre-Tax Profit Margin | 41.7 | % |
| Assets Turnover | 0.3 | % |
| Return on Assets (ROA) | 11.7 | % |
| Return on Equity (ROE) | 15.4 | % |
| Return on Capital Invested (ROCI) | 15.3 | % |
| Current Ratio | 2.5 | |
| Leverage Ratio (Assets/Equity) | 1.3 | |
| Interest Cover | 125.2 | |
| Total Debt/Equity (Gearing Ratio) | 0.02 | |
| LT Debt/Total Capital | 1.0 | % |
| Working Capital pS | 0.69 | $ |
| Cash pS | 0.47 | $ |
| Book-Value pS | 2.39 | $ |
| Tangible Book-Value pS | 2.21 | $ |
| Cash Flow pS | 0.41 | $ |
| Free Cash Flow pS | 0.15 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 1.96 | |
| Price/Tangible Book Ratio | 2.12 | |
| Price/Cash Flow | 11.5 | |
| Price/Free Cash Flow | 31.7 | |
| P/E as % of Industry Group | 58.0 | % |
| P/E as % of Sector Segment | 22.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -0.8 | 98 | 1,307 | 591 |
| 4 Weeks | 5.63 | 3.50 | 4.02 | 16.4 | 109 | 889 | 15,119 |
| 13 Weeks | 5.64 | 2.88 | 2.95 | 58.6 | 148 | 920 | 56,104 |
| 26 Weeks | 5.64 | 2.00 | 2.70 | 73.3 | 144 | 557 | 69,672 |
| 52 Weeks | 5.64 | 0.91 | 1.39 | 236.7 | 273 | 488 | 121,608 |
| YTD | 5.64 | 0.91 | - | 138.8 | 195 | 522 | 118,478 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 4.78 | 4.78 | 4.58 | 3.38 | 2.89 | 2.03 | 2.09 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 2.99 | 19.4 | 2.59 |
| Income | -1.02 | 1.3 | 1.88 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 40.46 | NA | 50.93 |
| R&D | 0.00 | NA | 0.00 |
| Normalized Inc. | -1.02 | NA | 1.88 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -17.8 | -64.0 | 40.7 |
| Earnings % | -7.8 | -84.6 | 48.7 |
| EPS % | -9.4 | -85.0 | 50.0 |
| EPS $ | -0.03 | -0.17 | 0.13 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 35.56 |
| Current Ratio | 3.2 |
| Quick Ratio (Acid Test) | 2.5 |
| Liquidity Ratio (Cash) | 1.33 |
| Receivables Turnover | 2.2 |
| Average Collection Period | 164 |
| Working Capital/Equity | 48.9 |
| Working Capital pS | 1.02 |
| Cash-Flow pS | 0.43 |
| Free Cash-Flow pS | -0.20 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 5.11 |
| Financial Leverage Ratio (Assets/Equity) | 1.4 |
| Debt Ratio | 27.3 |
| Total Debt/Equity (Gearing Ratio) | 0.03 |
| LT Debt/Equity | 0.01 |
| LT Debt/Capital Invested | 14.8 |
| LT Debt/Total Liabilities | 3.8 |
| Interest Cover | 113.8 |
| Interest/Capital Invested | 0.16 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 3.32 |
| Tobin's Q Ratio | 1.63 |
| Current P/E Ratio - LTM | 13.00 |
| Enterprise Value (EV)/EBITDA | 9.37 |
| Enterprise Value (EV)/Free Cash Flow | -25.25 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 2.12 |
| Price/Book Ratio - LTM | 1.96 |
| Price/Cash Flow Ratio | 11.5 |
| Price/Free Cash Flow Ratio - LTM | 31.7 |
| Price/Sales Ratio | 5.00 |
| P/E Ratio (1 month ago) - LTM | 11.9 |
| P/E Ratio (26 weeks ago) - LTM | 5.9 |
| P/E Ratio (52 weeks ago) - LTM | 3.8 |
| 5-Y High P/E Ratio | 34.2 |
| 5-Y Low P/E Ratio | 1.9 |
| 5-Y Average P/E Ratio | 10.4 |
| Current P/E Ratio as % of 5-Y Average P/E | 125 |
| P/E as % of Industry Group | 58.0 |
| P/E as % of Sector Segment | 22.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 13.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.03 |
| Current Liabilities pS | 0.47 |
| Tangible Book Value pS - LTM | 2.21 |
| Book Value pS - LTM | 2.39 |
| Capital Invested pS | 2.12 |
| Cash pS - LTM | 0.47 |
| Cash Flow pS - LTM | 0.41 |
| Free Cash Flow pS - LTM | 0.15 |
| Earnings pS (EPS) | 0.39 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -18.78 |
| Free Cash Flow Margin 5YEAR AVG | 19.18 |
| Net Profit Margin | 35.8 |
| Net Profit Margin - 5YEAR AVRG. | 38.8 |
| Equity Productivity | 0.52 |
| Return on Equity (ROE) | 18.6 |
| Return on Equity (ROE) - 5YEAR AVRG. | 22.5 |
| Capital Invested Productivity | 0.51 |
| Return on Capital Invested (ROCI) | 18.3 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 21.3 |
| Assets Productivity | 0.40 |
| Return on Assets (ROA) | 13.5 |
| Return on Assets (ROA) - 5YEAR AVRG. | 17.1 |
| Gross Profit Margin | 69.5 |
| Gross Profit Margin - 5YEAR AVRG. | 74.7 |
| EBITDA Margin - LTM | 46.0 |
| EBIT Margin - LTM | 42.0 |
| Pre-Tax Profit Margin | 41.8 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 50.7 |
| Effective Tax Rate | 7.3 |
| Effective Tax Rate - 5YEAR AVRG. | 6.2 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 307 |
| Revenue per Employee | 49,870 |
| Net Income per Employee | 17,855 |
| Average Collection Period | 189 |
| Receivables Turnover | 2.2 |
| Day's Inventory Turnover Ratio | 118 |
| Inventory Turnover | 3.1 |
| Inventory/Sales | 10.8 |
| Accounts Payble/Sales | 34.26 |
| Assets/Revenue | 2.50 |
| Net Working Capital Turnover | 1.06 |
| Fixed Assets Turnover | 0.79 |
| Total Assets Turnover | 0.4 |
| Revenue per $ Cash | 1.72 |
| Revenue per $ Plant | 0.94 |
| Revenue per $ Common Equity | 0.52 |
| Revenue per $ Capital Invested | 0.51 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 24.0 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 20.3 |
| Research & Devlopment (R&D) as % of Revenue | 0.0 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 0.0 |
|
|  
|
| |
 |  |